• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Castle Biosciences Inc (NQ: CSTL )

    33.64 +0.49 (+1.48%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 721,322
    Open 32.56
    Bid (Size) 34.50 (1)
    Ask (Size) 36.00 (20)
    Prev. Close 33.15
    Today's Range 32.13 - 34.29
    52wk Range 16.20 - 35.42
    Shares Outstanding 25,167,365
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Castle Biosciences Reports Third Quarter 2024 Results
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett’s Esophagus Patients
    From Castle Biosciences Inc.
    Via Business Wire

    Performance

    YTD
    +53.19%
    +53.19%
    1 Month
    +14.62%
    +14.62%
    3 Month
    +53.96%
    +53.96%
    6 Month
    +37.81%
    +37.81%
    1 Year
    +86.27%
    +86.27%

    More News

    Read More
    The Analyst Landscape: 4 Takes On Castle Biosciences
    Via Benzinga
    Momentum Has Narrowed Again, Significantly
    Via Talk Markets
    Sotera Health Stock Earns 91 RS Rating
    Via Investor's Business Daily
    Castle Biosciences to Participate in Upcoming Investor Conferences
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b Tumors
    From Castle Biosciences Inc.
    Via Business Wire
    Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant Potential
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences to Release Third Quarter 2024 Financial Results and Host Conference Call on Monday, Nov. 4, 2024
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences to Support the 71st Annual Montagna Symposium on the Biology of the Skin
    From Castle Biosciences Inc.
    Via Business Wire
    New Prospective, Multicenter Study Presented at SMR Demonstrates Castle Biosciences’ DecisionDx®-Melanoma Test Provides Significant Risk Prediction for Patients with Cutaneous Melanoma, Adding Value to Current Stage-Based Treatment Pathway Decisions
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences Hosts Groundbreaking Ceremony at Site of New Corporate Headquarters in Friendswood, Texas
    From Castle Biosciences Inc.
    Via Business Wire
    New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma
    From Castle Biosciences Inc.
    Via Business Wire
    New Data at AFS 2024 Demonstrates the Strength of Castle Biosciences’ TissueCypher® Test in Independently Predicting Risk of Developing Esophageal Cancer, Guiding Risk-Aligned Management Decisions for Patients with Barrett’s Esophagus
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year
    From Castle Biosciences Inc.
    Via Business Wire
    DecisionDx®-Melanoma Can Identify Melanoma Patients with Low Risk of Sentinel Lymph Node Positivity Who May Safely Forego Biopsy Surgery, New Independent Study Affirms
    From Castle Biosciences Inc.
    Via Business Wire
    Study Confirms the Ability of Castle Biosciences' DecisionDx®-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences to Participate in Upcoming Investor Conferences
    From Castle Biosciences Inc.
    Via Business Wire
    Yum China Posts Upbeat Earnings, Joins Clear Secure, TG Therapeutics, Bioventus And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    CSTL Stock Earnings: Castle Biosciences Beats EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    Castle Biosciences Reports Second Quarter 2024 Results
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference
    From Castle Biosciences Inc.
    Via Business Wire
    ON Semiconductor Posts Upbeat Earnings, Joins Oil States International, CommScope Holding And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Castle Biosciences and Skin Cancer Survivor Teddi Mellencamp Arroyave Launch Campaign to Increase Awareness of Melanoma
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences to Release Second Quarter 2024 Financial Results and Host Conference Call on Monday, Aug. 5, 2024
    From Castle Biosciences Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.